Testosterone Suspension: The Fastest-Acting Pre-Workout Testosterone

Testosterone suspension is the simplest possible form of injectable testosterone: pure, unesterified testosterone hormone dispersed in an aqueous (water-based) vehicle rather than dissolved in oil. With no ester chain attached to slow its release, the hormone enters circulation almost immediately after injection. This single distinction — the absence of an ester — is responsible for everything that makes suspension unusual among injectable anabolic-androgenic steroids (AAS): the near-instant serum spike, the very short half-life, the necessity of frequent dosing, and the notorious injection-site discomfort.

In research and physique contexts, suspension occupies a narrow niche. It is not used as a base hormone for a multi-week cycle the way esterified testosterone is, because maintaining stable levels would require multiple daily injections. Instead, it is most often discussed as a pre-workout or pre-competition compound, timed to deliver a sharp, transient peak in circulating testosterone in the hour before training. Vingren et al. (2010) reviewed the regulatory role of testosterone in resistance exercise, and it is this acute up-stream signaling — combined with the subjective effects of a rapid androgen surge — that underlies the pre-workout rationale.

This guide examines what suspension is at the molecular and pharmacokinetic level, the mechanism behind its pre-workout use, the considerable practical drawbacks (painful injections, dosing frequency, post-injection pain, and the role of particle size), the dose ranges reported in the literature, the side-effect profile, and the bloodwork and harm-reduction considerations that any serious researcher should understand before working with an ester-free aqueous testosterone.

Pharmacological Profile

Testosterone Suspension (Test No Ester / TNE)

• Classification: Aqueous (water-based) suspension of unesterified testosterone; injectable androgen.
• Active hormone: Testosterone itself, identical to endogenous testosterone — no ester, no chemical modification of the steroid nucleus.
• Vehicle: Micronized testosterone particles suspended in sterile water with a wetting agent, a suspending agent, and a preservative. It is a suspension, not a true solution, because testosterone is poorly water-soluble.
• Onset: Rapid; appreciable serum elevation within minutes, with peak concentrations generally reported in the 30–60 minute range.
• Half-life: Very short — on the order of hours rather than days. Because nothing slows absorption, the compound clears far faster than any esterified testosterone.
• Aromatization: Yes, and rapidly. As unmodified testosterone, suspension is a substrate for aromatase and converts to estradiol; the sharp peak produces a correspondingly sharp estrogenic load.
• Detection vs. esters: Distinct pharmacokinetics from oil-based esters such as Test Cypionate→ or propionate, which release the hormone gradually as the ester is cleaved.

The essential point is that suspension and an esterified testosterone deliver the same hormone. The ester is not part of the active molecule — it is a release-rate modifier. Once an ester such as cypionate, enanthate, or propionate is enzymatically cleaved in the body, what remains is identical to suspension testosterone. The ester's only job is to govern how quickly the hormone becomes available. Suspension simply removes that governor entirely.

Mechanism and Why It Is Used Pre-Workout

Testosterone, esterified or not, exerts its effects by binding the androgen receptor (AR). The receptor-ligand complex translocates to the nucleus and modulates transcription of androgen-responsive genes, with downstream effects on muscle protein synthesis, nitrogen retention, and erythropoiesis. Sokol et al. (1982) characterized the kinetics of injectable testosterone in eugonadal and hypogonadal men, establishing the basic absorption behavior that the ester-versus-no-ester distinction modifies. Bhasin et al. (1996) demonstrated that supraphysiologic testosterone increases muscle size and strength, and Storer et al. (2003) showed that testosterone dose-dependently increases maximal voluntary strength and leg power. These are the long-run anabolic effects that accrue from sustained elevated testosterone over weeks.

The pre-workout rationale for suspension is different in character. It is not built on the slow accumulation of muscle protein but on the acute, transient effects of a rapid androgen spike timed to a training session. Because the unesterified hormone peaks within roughly half an hour to an hour, an injection taken before training produces its highest circulating concentration during the workout itself. Three classes of acute effect are commonly invoked:

• Pump and vasodilation. Users report a pronounced muscle "pump" — increased intramuscular blood volume during training. Part of this is attributed to androgen effects on the vasculature and to the rapid hormonal shift.
• Aggression and drive. Wood and Stanton (2012) reviewed testosterone and sport, including behavioral dimensions. A sharp androgen surge is frequently described as increasing training aggression, focus, and pain tolerance — psychological factors that subjectively raise training intensity.
• Strength and power. Vingren et al. (2010) described testosterone as an up-stream regulatory element in resistance exercise. The acute peak is believed by users to translate into a short-lived strength and power increase for the session, though the controlled evidence for an acute (same-session) ergogenic effect is far weaker than the evidence for chronic anabolic adaptation.

It is important to keep the evidence boundaries clear. The trials that establish testosterone's strength and hypertrophy effects (Bhasin 1996; Storer 2003) used sustained administration over weeks, not single pre-workout injections. The pre-workout use of suspension rests substantially on user-reported acute experience and on the plausible-but-not-rigorously-demonstrated assumption that a same-session androgen peak meaningfully enhances that session's output. Researchers should treat the acute ergogenic claim as a hypothesis supported by mechanism and anecdote rather than by controlled trial data.

The Practical Realities

The pharmacokinetics that make suspension attractive in theory create a set of practical problems that dominate the real-world experience of using it.

Painful injections and post-injection pain (PIP). Suspension is widely reported to be among the most uncomfortable injectables. Because it is a water-based suspension of solid microparticles rather than an oil solution, the injected material includes undissolved crystalline testosterone that physically irritates the muscle tissue. Svendsen and Blom (1984) studied intramuscular injection damage as a function of concentration, volume, injection speed, and vehicle — the exact variables that govern suspension's discomfort. Their work establishes that the vehicle and concentration of an injectable directly affect the degree of local muscle damage, which is precisely why an aqueous crystalline suspension behaves so differently from an oil ester. PIP from suspension is often described as immediate (a sharp sting on injection) as well as delayed (soreness over the following hours to days).

Particle size matters. The defining quality variable for a suspension is the micron particle size of the milled testosterone. Finely micronized particles disperse more evenly, pass through a needle more reliably, and irritate tissue less. Coarsely milled or poorly suspended product is more likely to clog the needle, settle out of the vehicle, and cause more severe PIP. This is why suspension quality is far more variable between sources than esterified oils: the same hormone can be far more or far less tolerable depending entirely on how finely it was milled and how well it stays suspended.

Frequent dosing. The very short half-life means a single injection does not hold elevated levels for long. To maintain anything resembling stable testosterone, suspension would have to be injected multiple times per day — which is why it is essentially never used as a stand-alone cycle base. Its use case is inherently intermittent: injected when an acute peak is wanted (before training or competition), not as a steady-state hormone.

Needle and handling issues. Because solid particles can settle, the vial must be agitated before drawing, and the suspension can separate in the syringe if not injected promptly. Larger particles raise the practical risk of needle blockage. These handling demands add friction that esterified oils do not impose.

Dosing and Protocol (Research Framing)

The literature describing controlled human testosterone administration (Bhasin et al. 1996; Storer et al. 2003; Coviello et al. 2008) used esterified preparations dosed on a weekly basis, not aqueous suspension dosed acutely. There is therefore no robust controlled dataset establishing an "optimal" pre-workout suspension dose. The dose ranges discussed in observational and physique-research contexts should be read against that gap.

In those contexts, suspension is described as being used in the approximate range of 50–100 mg per pre-workout injection, administered shortly before training on training days only. Some sources describe daily or near-daily administration on a per-session basis; others describe it layered on top of an esterified testosterone base (the ester providing the stable background level, the suspension providing an acute pre-workout spike on top of it).

Several points follow from the pharmacology:

• Because the half-life is measured in hours, the dose is fundamentally a single-event peak, not a level to be maintained. The relevant question is the magnitude of the acute peak, not a weekly total in the way it would be for an ester.
• Timing is the whole point. The injection is taken with enough lead time to peak during training — generally interpreted as 30–60 minutes prior, consistent with the reported time-to-peak.
• The total weekly androgen exposure when suspension is stacked on top of an ester base can be substantially higher than the ester alone, and the side-effect profile scales accordingly.

Researchers should note that the absence of controlled dose-response data for acute pre-workout testosterone means any specific number is an extrapolation from steady-state ester studies and from self-report, not a validated protocol.

Side Effects

Suspension's side-effect profile is the standard testosterone profile, but compressed and intensified by the rapid, spiking kinetics — plus a distinct set of injection-related risks that oil esters largely avoid.

Rapid aromatization and estrogenic load. As unmodified testosterone, suspension aromatizes to estradiol, and it does so on the same accelerated timescale as everything else about the compound. The sharp serum peak drives a correspondingly sharp rise in estrogen. Estrogenic effects — water retention, blood pressure elevation, gynecomastia risk over time, and mood effects — can therefore appear more abruptly than with the smoother curve of a long ester. Handelsman and Wartofsky (2013) emphasized the requirement for mass-spectrometry-grade assays to measure sex steroids accurately, which is directly relevant to anyone attempting to track estradiol against a spiking testosterone curve.

HPG-axis suppression. Like all exogenous androgens, suspension suppresses endogenous testosterone production through negative feedback on the hypothalamic-pituitary-gonadal axis. Suppression is a function of cumulative androgen exposure, so the degree depends on how frequently suspension is used and whether it is stacked on an ester base. It is not avoided by the short half-life — repeated peaks still signal suppression.

Lipid and cardiovascular effects. Testosterone administration adversely shifts the lipid profile and carries cardiovascular signals. Basaria et al. (2010) reported adverse cardiovascular-related events associated with testosterone administration in an older population, and Coviello et al. (2008) documented dose-dependent increases in erythropoiesis (hematocrit/red cell mass) with graded testosterone doses. Elevated hematocrit raises blood viscosity and is one of the more important monitorable risks of any testosterone protocol.

Injection-site and infection risk. This is where suspension diverges most from oil esters. The combination of frequent injections, a water-based vehicle, crystalline particulate, and the local tissue trauma that Svendsen and Blom (1984) characterized creates elevated risk of injection-site reactions, sterile abscess, and — critically — infection. Frequent injections multiply the number of skin punctures and therefore the cumulative opportunity for bacterial introduction. Aqueous suspensions also offer less of the antimicrobial buffering that some oil preparations incidentally provide. Poor aseptic technique under these conditions is a meaningful route to local and potentially systemic infection.

Androgenic effects. Standard androgenic effects — acne, accelerated male-pattern hair loss in predisposed individuals, and prostate-related effects — apply as they do to any testosterone, scaled to total exposure.

Bloodwork

Anyone working with an aqueous testosterone should monitor the same panel relevant to any testosterone protocol, with particular attention to the markers most affected by spiking kinetics and frequent injection:

• Total and free testosterone — noting that an accurate reading depends heavily on timing relative to the last injection given suspension's volatile curve. Handelsman and Wartofsky (2013) underscore that mass-spectrometry assays are required for reliable sex-steroid measurement; immunoassays are unreliable at the relevant concentrations.
• Estradiol (E2) — best measured by a sensitive (LC-MS/MS) assay, because the rapid aromatization can drive estradiol up quickly and immunoassay E2 is notoriously inaccurate in men.
• Hematocrit and hemoglobin — to track the erythropoietic effect documented by Coviello et al. (2008); rising hematocrit is a primary safety signal.
• Lipid panel (HDL, LDL) — testosterone, like other AAS, suppresses HDL.
• Blood pressure — driven by estrogenic water retention and hematocrit; not strictly bloodwork but monitored alongside it.
• LH and FSH — to gauge the degree of HPG-axis suppression.

Timing of the draw matters more for suspension than for any ester. A sample taken at the post-injection peak and one taken at trough can differ enormously, so consistency in timing relative to dosing is essential for interpretable trends.

Harm Reduction

For researchers who proceed, the harm-reduction priorities follow directly from the compound's two defining hazards — its spiking estrogenic load and its injection burden.

• Aseptic technique is non-negotiable. Because frequent injections of a crystalline aqueous suspension elevate infection risk, every injection should use a fresh sterile needle, proper skin antisepsis, and a vial that has not been compromised. The cumulative puncture count is the single largest infection variable.
• Particle quality. Prefer finely micronized, well-suspended material. Coarse or settling product raises both PIP and needle-blockage risk. Agitate the vial before every draw and inject promptly before the suspension separates.
• Rotate injection sites. Frequent dosing in a single site compounds the local trauma Svendsen and Blom (1984) described. Rotation reduces cumulative damage and scar tissue.
• Manage estrogen deliberately, not blindly. The rapid aromatization means estradiol can climb fast. Track it with a sensitive assay rather than dosing an aromatase inhibitor on guesswork — over-suppressing estradiol carries its own lipid, bone, libido, and mood consequences.
• Monitor hematocrit. Rising hematocrit is the cardiovascular signal most likely to require intervention; Coviello et al. (2008) established its dose dependence.
• Do not treat it as a cycle base. Suspension is an acute-peak tool. Attempting to run stable levels on suspension alone means many injections per day and a correspondingly multiplied injection-risk profile. Where a stable background is wanted, that is the role of an ester.
• Plan recovery. Because suspension still suppresses the HPG axis (Wood and Stanton 2012 review the broader endocrine context), any meaningful use should be planned with post-use recovery in mind.

Frequently Asked Questions

What makes testosterone suspension different from regular injectable testosterone?

The hormone is identical — both deliver testosterone. The difference is the absence of an ester. Esterified testosterones (cypionate, enanthate, propionate) attach a fatty-acid chain that must be enzymatically cleaved before the hormone is active, which slows and smooths release over days. Suspension has no ester, so the hormone is immediately available, peaks within 30–60 minutes, and clears within hours. It is the same testosterone with the release-rate brake removed.

Why is suspension injected before a workout instead of on a schedule?

Because its half-life is measured in hours, a single injection cannot maintain elevated levels for long. Rather than fight that with multiple daily injections, the typical use times one injection to peak during a training session — exploiting the acute androgen surge for subjective pump, aggression, and strength during the workout. The effect that is being chased is the short transient peak, not a stable level.

Why is testosterone suspension so painful to inject?

It is a water-based suspension of solid micronized testosterone particles, not an oil solution. The undissolved crystalline material physically irritates muscle tissue, and the aqueous vehicle disperses differently from oil. Svendsen and Blom (1984) showed that vehicle, concentration, volume, and injection speed all influence muscle damage — and a crystalline aqueous suspension is close to a worst case on several of those axes. Finer particle milling reduces, but does not eliminate, the discomfort.

Does suspension cause more estrogen side effects than esters?

It can appear to, because the estrogen rises as sharply as the testosterone does. The compound aromatizes to the same extent as any unmodified testosterone, but the rapid peak compresses the estrogenic load into a short, intense window rather than the smoother curve of a long ester. That abruptness is why water retention and related effects can feel more sudden.

Is the infection risk really higher with suspension?

The infection risk is elevated mainly because of injection frequency, not the hormone itself. Maintaining any meaningful use requires far more injections than a long ester, and each puncture is an opportunity for contamination. Combined with crystalline particulate and an aqueous vehicle, this makes strict aseptic technique more important with suspension than with almost any other injectable.

Conclusion

Testosterone suspension is testosterone in its most stripped-down injectable form — the same hormone as any ester, with the ester's release-rate brake removed. That single change produces a near-immediate peak, a half-life measured in hours, and a narrow, specific use case: an acute pre-workout or pre-competition androgen spike rather than a cycle base. The mechanism behind the pre-workout rationale is plausible and grounded in testosterone's established up-stream role in resistance exercise (Vingren et al. 2010), but the controlled evidence for testosterone's muscle and strength effects (Bhasin 1996; Storer 2003) comes from sustained administration, not single acute injections — so the same-session ergogenic claim remains substantially anecdotal.

Against that uncertain acute benefit sits a concrete and well-characterized set of costs: notorious post-injection pain driven by crystalline particulate and vehicle (Svendsen and Blom 1984), a dosing frequency that multiplies injection and infection risk, rapid aromatization that drives estrogen up as fast as testosterone, and the standard hematocrit, lipid, and HPG-suppression burden of any testosterone (Coviello et al. 2008; Basaria et al. 2010). Particle size is the quality variable that most distinguishes a tolerable suspension from an intolerable one. Any researcher working with an aqueous testosterone should weigh the acute, partly anecdotal benefit against these tangible risks, monitor with sensitive mass-spectrometry-grade assays (Handelsman and Wartofsky 2013), and treat aseptic technique as the central harm-reduction priority.

References:

1. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 1996;335(1):1-7.
2. Nieschlag E, Behre HM, Nieschlag S. Testosterone: Action, Deficiency, Substitution. 4th ed. Cambridge University Press; 2012.
3. Sokol RZ, Palacios A, Campfield LA, et al. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril. 1982;37(3):425-430.
4. Wood RI, Stanton SJ. Testosterone and sport: current perspectives. Horm Behav. 2012;61(1):147-155.
5. Svendsen O, Blom L. Intramuscular injections and muscle damage: effects of concentration, volume, injection speed and vehicle. Arch Toxicol Suppl. 1984;7:472-475.
6. Coviello AD, Kaplan B, Lakshman KM, et al. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008;93(3):914-919.
7. Handelsman DJ, Wartofsky L. Requirement for mass spectrometry sex steroid assays in the Journal of Clinical Endocrinology and Metabolism. J Clin Endocrinol Metab. 2013;98(10):3971-3973.
8. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-122.
9. Storer TW, Magliano L, Woodhouse L, et al. Testosterone dose-dependently increases maximal voluntary strength and leg power. J Clin Endocrinol Metab. 2003;88(4):1478-1485.
10. Vingren JL, Kraemer WJ, Ratamess NA, et al. Testosterone physiology in resistance exercise and training: the up-stream regulatory elements. Sports Med. 2010;40(12):1037-1053.

Disclaimer: This article is for educational and harm-reduction purposes only. Anabolic steroids carry health risks. Consult a healthcare provider before using any performance-enhancing substances. In Canada, anabolic steroids are Schedule IV controlled substances under the CDSA.